{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T16:52:43Z","timestamp":1782579163510,"version":"3.54.5"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>The traditional Japanese (Kampo) medicine, kakkonto with shosaikotokakikyosekko, has antiviral and anti-inflammatory effects. In this randomized trial, patients with mild and moderate coronavirus disease (COVID-19) were randomly allocated to the control group receiving conventional treatment for symptom relief such as antipyretics and antitussives or the Kampo group receiving mixed extract granules of kakkonto (2.5\u00a0g) and shosaikotokakikyosekko (2.5\u00a0g) three times a day for 14\u00a0days in addition to conventional treatment. The main outcome was the number of days until total symptom relief. The secondary outcome was the number of days until each symptom\u2019s relief and whether the disease progressed to respiratory failure. We enrolled a total of 161 patients (Kampo group, <jats:italic>n<\/jats:italic> = 81; control group, <jats:italic>n<\/jats:italic> = 80). The results from Kaplan\u2013Meier estimates of symptom relief showed that there are no significant differences between the groups. However, covariate-adjusted cumulative incidence of fever relief considering competitive risk showed that the recovery was significantly faster in the Kampo group than in the control group (HR 1.76, 95% CI 1.03\u20133.01). Additionally, the risk of disease progression to moderate COVID-19 requiring oxygen inhalation was lower in the Kampo group than in the control group (Risk Difference \u22120.13, 95% CI \u22120.27\u20130.01). No significant drug-related side effects were observed. Kakkonto with shosaikotokakikyosekko is effective for fever relief with suppression of disease progression in COVID-19 patients.<\/jats:p><jats:p><jats:bold>Clinical Trial Registration:<\/jats:bold><jats:ext-link>https:\/\/jrct.niph.go.jp\/en-latest-detail\/jRCTs021200020<\/jats:ext-link>, identifier [jRCTs021200020]<\/jats:p>","DOI":"10.3389\/fphar.2022.1008946","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T06:46:22Z","timestamp":1667976382000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Multicenter, randomized controlled trial of traditional Japanese medicine, kakkonto with shosaikotokakikyosekko, for mild and moderate coronavirus disease patients"],"prefix":"10.3389","volume":"13","author":[{"given":"Shin","family":"Takayama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Namiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryutaro","family":"Arita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Ohsawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsumi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Nakae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuhiro","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Ishigami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Nochioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Airi","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Mimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuhiro","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akito","family":"Hisanaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Mitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1620\/tjem.2022.J040","article-title":"Refractory chest pain in mild to moderate coronavirus disease 2019 successfully treated with saikanto, a Japanese traditional medicine","volume":"257","author":"Arita","year":"2022","journal-title":"Tohoku J. Exp. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/tkm2.1258","article-title":"Kakkonto, shosaikoto, Platycodon grandiflorum root, and gypsum (a Japanese original combination drug known as saikatsugekito): Pharmacological review of its activity against viral infections and respiratory inflammatory conditions and a discussion of its applications to COVID \u201019","volume":"7","author":"Arita","year":"2020","journal-title":"Traditional Kampo Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2201662","article-title":"Randomized trial of metformin, ivermectin, and fluvoxamine for covid-19","volume":"387","author":"Bramante","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1001\/jamainternmed.2021.6759","article-title":"Efficacy of inhaled Ciclesonide for outpatient treatment of adolescents and adults with symptomatic COVID-19: A randomized clinical trial","volume":"182","author":"Clemency","year":"2022","journal-title":"JAMA Intern. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1007\/s40265-021-01620-z","article-title":"Casirivimab\/Imdevimab: First approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"B43","unstructured":"STORK2022"},{"key":"B9","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/S0140-6736(20)31862-6","article-title":"Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (coalition II): A randomised clinical trial","volume":"396","author":"Furtado","year":"2020","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S1875-5364(19)30079-2","article-title":"Exploration of the mechanisms of Ge gen decoction against influenza A virus infection","volume":"17","author":"Geng","year":"2019","journal-title":"Chin. J. Nat. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1056\/NEJMoa2116846","article-title":"Early remdesivir to prevent progression to severe Covid-19 in outpatients","volume":"386","author":"Gottlieb","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B8","unstructured":"Drug guideline - Molnupiravir (LAGEVRIO\u00ae)2022"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1001\/jama.2022.2832","article-title":"Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: A randomized clinical trial","volume":"327","author":"Gupta","year":"","journal-title":"JAMA"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","article-title":"Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab","volume":"385","author":"Gupta","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e2276","DOI":"10.1002\/rmv.2276","article-title":"Hydroxychloroquine in the treatment of coronavirus disease 2019: Rapid updated systematic review and meta-analysis","volume":"32","author":"Gupta","year":"","journal-title":"Rev. Med. Virol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(21)00947-8","article-title":"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: An observational study using national surveillance data","volume":"397","author":"Harrs","year":"2021","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"112057","DOI":"10.1016\/j.fct.2021.112057","article-title":"Glossary of phytoconstituents: Can these be repurposed against sars CoV-2? A quick in silico screening of various phytoconstituents from plant Glycyrrhiza glabra with sars CoV-2 main protease","volume":"150","author":"Hejazi","year":"2021","journal-title":"Food Chem. Toxicol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"B19","doi-asserted-by":"publisher","first-page":"153242","DOI":"10.1016\/j.phymed.2020.153242","article-title":"Efficacy and safety of lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial","volume":"85","author":"Hu","year":"2021","journal-title":"Phytomedicine."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e14262","DOI":"10.1111\/jfbc.14262","article-title":"Structural interactions of phytoconstituent(s) from cinnamon, bay leaf, oregano, and parsley with SARS-CoV-2 nucleocapsid protein: A comparative assessment for development of potential antiviral nutraceuticals","author":"Husain","year":"2022","journal-title":"J. Food Biochem."},{"key":"B21","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/tkm2.1261","article-title":"Three mild cases of coronavirus disease 2019 treated with saikatsugekito, a Japanese herbal medicine","volume":"8","author":"Irie","year":"","journal-title":"Traditional Kampo Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/tkm2.1290","article-title":"Treatment of coronavirus disease 2019 with saikatsugekito: A case series","volume":"8","author":"Irie","year":"","journal-title":"Traditional Kampo Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.7326\/M22-0729","article-title":"Effect of molnupiravir on biomarkers, respiratory interventions, and medical services in COVID-19 : A randomized, placebo-controlled trial","volume":"175","author":"Johnson","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"804103","DOI":"10.3389\/fphar.2022.804103","article-title":"In vitro suppression of SARS-CoV-2 infection by existing Kampo formulas and crude constituent drugs used for treatment of common cold respiratory symptoms","volume":"13","author":"Kakimoto","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1038\/s12276-021-00624-9","article-title":"Platycodin D, a natural component of Platycodon grandiflorum, prevents both lysosome- and TMPRSS2-driven SARS-CoV-2 infection by hindering membrane fusion","volume":"53","author":"Kim","year":"2021","journal-title":"Exp. Mol. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1080\/14756366.2021.1873977","article-title":"Scutellaria baicalensis extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease in vitro","volume":"36","author":"Liu","year":"2021","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1007\/s00216-021-03233-7","article-title":"Screening and evaluation of anti-SARS-CoV-2 components from Ephedra sinica by ACE2\/CMC-HPLC-IT-TOF-MS approach","volume":"413","author":"Lv","year":"2021","journal-title":"Anal. Bioanal. Chem."},{"key":"B29","doi-asserted-by":"publisher","first-page":"44098","DOI":"10.1038\/srep44098","article-title":"Distribution analysis via mass spectrometry imaging of ephedrine in the lungs of rats orally administered the Japanese kampo medicine maoto","volume":"7","author":"Matsumoto","year":"2017","journal-title":"Sci. Rep."},{"key":"B31","volume-title":"Guide to medical treatment for COVID-19 version 7.2","year":"2022"},{"key":"B32","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.jiac.2022.03.014","article-title":"Maoto, a traditional herbal medicine, for post-exposure prophylaxis for Japanese healthcare workers exposed to COVID-19: A single center study","volume":"28","author":"Nabeshima","year":"2022","journal-title":"J. Infect. Chemother."},{"key":"B33","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jama.2021.24939","article-title":"Effect of subcutaneous casirivimab and imdevimab antibody combination vs placebo on development of symptomatic COVID-19 in early asymptomatic SARS-CoV-2 infection: A randomized clinical trial","volume":"327","author":"O\u2019Brien","year":"2022","journal-title":"JAMA"},{"key":"B34","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/s0192-0561(00)00007-2","article-title":"Modulation of lung local immune responses by oral administration of a herbal medicine Sho-saiko-to","volume":"22","author":"Ohtake","year":"2000","journal-title":"Int. J. Immunopharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"844072","DOI":"10.3389\/fphar.2022.844072","article-title":"Kampo medicine promotes early recovery from coronavirus disease 2019-related olfactory dysfunction: A retrospective observational study","volume":"13","author":"Ono","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1016\/j.csbj.2020.11.010","article-title":"Chinese herbal compounds against SARS-CoV-2: Puerarin and quercetin impair the binding of viral S-protein to ACE2 receptor","volume":"18","author":"Pan","year":"2020","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"B37","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.jiph.2021.03.015","article-title":"Efficacy and safety of lopinavir-ritonavir in COVID-19: A systematic review of randomized controlled trials","volume":"14","author":"Patel","year":"2021","journal-title":"J. Infect. Public Health"},{"key":"B38","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","article-title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody","volume":"583","author":"Pinto","year":"2020","journal-title":"Nature"},{"key":"B39","doi-asserted-by":"publisher","first-page":"4618","DOI":"10.1080\/07391102.2020.1779129","article-title":"In silico identification of potential inhibitors from Cinnamon against main protease and spike glycoprotein of SARS CoV-2","volume":"39","author":"Prasanth","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"B40","doi-asserted-by":"publisher","first-page":"103856","DOI":"10.1016\/j.ebiom.2022.103856","article-title":"Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b\/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics","volume":"76","author":"Quinn","year":"2022","journal-title":"EBiomedicine"},{"key":"B41","doi-asserted-by":"publisher","first-page":"687818","DOI":"10.3389\/fphar.2021.687818","article-title":"Kakkonto inhibits cytokine production induced by rhinovirus infection in primary cultures of human nasal epithelial cells","volume":"12","author":"Saito","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.18502\/ijph.v50i5.6120","article-title":"In silico comparison of separate or combinatorial effects of potential inhibitors of the SARS-CoV-2 binding site of ACE2","volume":"50","author":"Shakhsi-Niaei","year":"2021","journal-title":"Iran. J. Public Health"},{"key":"B44","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1056\/NEJMc2207519","article-title":"Efficacy of antibodies and antiviral drugs against omicron BA.2.12.1, BA.4, and BA.5 subvariants","volume":"387","author":"Takashita","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1620\/tjem.254.71","article-title":"Treatment of COVID-19-related olfactory disorder promoted by kakkontokasenkyushin\u2019i: A case series","volume":"254","author":"Takayama","year":"","journal-title":"Tohoku J. Exp. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1186\/s13063-020-04746-9","article-title":"A multi-center, randomized controlled trial by the integrative management in Japan for epidemic disease (IMJEDI study-RCT) on the use of kampo medicine, kakkonto with shosaikotokakikyosekko, in mild-to-moderate COVID-19 patients for symptomatic relief and prevention of severe stage: A structured summary of a study protocol for a randomized controlled trial","volume":"21","author":"Takayama","year":"2020","journal-title":"Trials"},{"key":"B47","doi-asserted-by":"publisher","first-page":"656246","DOI":"10.3389\/fphar.2021.656246","article-title":"Prevention and recovery of COVID-19 patients with Kampo medicine: Review of case reports and ongoing clinical trials","volume":"12","author":"Takayama","year":"","journal-title":"Front. Pharmacol."},{"key":"B48","article-title":"Conventional and kampo medicine treatment for mild-to-moderate COVID-19: A multicenter, retrospective, observational study by the integrative management in Japan for epidemic disease (IMJEDI study-observation)","author":"Takayama","year":"2022","journal-title":"Intern Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1016\/j.ymthe.2021.05.005","article-title":"Plant-derived exosomal microRNAs inhibit lung inflammation induced by exosomes SARS-CoV-2 Nsp12","volume":"29","author":"Teng","year":"2021","journal-title":"Mol. Ther."},{"key":"B6","volume-title":"COVID-19 dashboard","year":"2022"},{"key":"B50","unstructured":"SARS-CoV-2 variant classifications and definitions"},{"key":"B51","volume-title":"Symptoms of COVID-19","year":""},{"key":"B52","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3390\/v13040609","article-title":"Glycyrrhizin Effectively Inhibits SARS-CoV-2 Replication by inhibiting the viral main protease","volume":"13","author":"van de Sand","year":"2021","journal-title":"Viruses"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1056\/nejmoa2108163","article-title":"REGEN-COV antibody combination and outcomes in outpatients with covid-19","volume":"385","author":"Weinrech","year":"2021","journal-title":"N. Engl. J. Med. Overseas. Ed."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00507-2","article-title":"Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: A retrospective cohort study","author":"Wong","year":"2022","journal-title":"Lancet Infect. Dis"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese center for disease control and prevention","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28138","article-title":"The outbreak of SARS-CoV-2 Omicron lineages, immune escape and vaccine effectivity","volume":"2022","author":"Yongbing","year":"2022","journal-title":"J. Med. Virol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"153364","DOI":"10.1016\/j.phymed.2020.153364","article-title":"Glycyrrhizic acid exerts inhibitory activity against the spike protein of SARS-CoV-2","volume":"85","author":"Yu","year":"2021","journal-title":"Phytomedicine."},{"key":"B57","doi-asserted-by":"publisher","first-page":"5230","DOI":"10.3390\/molecules26175230","article-title":"GC-MS, LC-MS\/MS, docking and molecular dynamics approaches to identify potential SARS-CoV-2 3-chymotrypsin-like protease inhibitors from Zingiber officinale roscoe","volume":"26","author":"Zubair","year":"2021","journal-title":"Molecules"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1008946\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T06:46:26Z","timestamp":1667976386000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1008946\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,9]]},"references-count":57,"alternative-id":["10.3389\/fphar.2022.1008946"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.1008946","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,9]]},"article-number":"1008946"}}